Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community. Issues are used to track todos, bugs, feature requests, and more.

Abstract: Sorting is a classic algorithm that is fundamental building block of many algorithms. Many algorithms requiring high speed data processing nowadays are hardware accelerated using ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Utah-based Recursion, a clinical-stage biotech company specialising in drug discovery, has entered into a definitive agreement to merge with Oxford-based Exscientia, a clinical-stage drug design and ...

After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Armed with a combined $850 million in cash, the companies said Thursday the resulting biotech will have a pipeline that could deliver 10 clinical readouts over the next 18 months. The AI-enabled ...